Trial · NCT07072793
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
NCT07072793, Completed, Pfizer; results first posted 2026-01-12
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe. Trials, record NCT07072793. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07072793
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- NCT number
- NCT07072793
- Status
- Completed
- Enrollment
- 131,005 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Interventions
- nirmatrelvir-ritonavir
- First posted
- 2025-07-18
- Last updated
- 2026-02-09
- Results first posted
- 2026-01-12
Source ClinicalTrials.gov
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants According to Age Group: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Age Group: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Sex: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Sex: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Region of Residence: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Region of residence was categorized into following categories: Northeast, North Central, South, West, and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Region of Residence: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Region of residence was categorized into following categories: Northeast, North Central, South, West and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Payer Type: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Payer Type: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Insurance Plan Type: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Insurance plan type was categorized into following categories: comprehensive/indemnity, exclusive/preferred provider organization (EPO/PPO), point of service capitation (POS) with or without capitation, health maintenance organization (HMO), consumer driven/ high-deductible health plan (CDHP/HDHP) and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
| Primary | Number of Participants According to Insurance Plan Type: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Insurance plan type was categorized into following categories: comprehensive/indemnity, EPO/PPO, POS with or without capitation, HMO, CDHP/HDHP and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 registered outcomesOutcomes42
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants According to Age Group: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Age Group: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Sex: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Sex: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Region of Residence: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Region of Residence: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Payer Type: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Payer Type: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Insurance Plan Type: Unmatched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were included and observed in this study. This outcome measure was planned to be reported for unmatched participants (treated and untreated). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Insurance Plan Type: Matched Participants | At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study | Analysis population included all eligible participants whose data were retrieved and observed in this study. This outcome measure was planned to be reported for matched participants (treated and untreated). Here, Overall Number of Participants Analyzed signifies the numbers which were matched/ adjusted based on pre-defined characteristics among actual enrolled population and was a pseudo population, hence these numbers are different from unmatched population (actual enrolled population). | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 outcomesResults by group624
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Treated: Absence Eligibility | 18-29 years | 57 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Untreated: Absence Eligibility | 18-29 years | 686 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Treated: Short-term Disability | 18-29 years | 545 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Untreated: Short-term Disability | 18-29 years | 6123 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Treated: Long-term Disability | 18-29 years | 556 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Untreated: Long-term Disability | 18-29 years | 6493 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Treated: Absence Eligibility | 30-39 years | 201 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Untreated: Absence Eligibility | 30-39 years | 1442 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Treated: Short-term Disability | 30-39 years | 2076 | Participants | |
| Number of Participants According to Age Group: Unmatched Participants | Unmatched Untreated: Short-term Disability | 30-39 years | 15168 | Participants |
1 to 10 of 624Source ClinicalTrials.gov
See all 624 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Unmatched Treated Cohort | 23,155 | |
| Overall Study | STARTED | Unmatched Untreated Cohort | 107,850 | |
| Overall Study | COMPLETED | Unmatched Treated Cohort | 23,155 | |
| Overall Study | COMPLETED | Unmatched Untreated Cohort | 107,850 | |
| Overall Study | NOT COMPLETED | Unmatched Treated Cohort | 0 | |
| Overall Study | NOT COMPLETED | Unmatched Untreated Cohort | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Unmatched Treated Cohort | 0 | 0 |
| Total, all-cause mortality | Unmatched Untreated Cohort | 0 | 0 |
| Total, other adverse events | Unmatched Treated Cohort | 0 | 0 |
| Total, other adverse events | Unmatched Untreated Cohort | 0 | 0 |
| Total, serious adverse events | Unmatched Treated Cohort | 0 | 0 |
| Total, serious adverse events | Unmatched Untreated Cohort | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Matched Treated: Long-term Disability vs Matched Untreated: Long-term Disability: Number of Participants With Any Long Term Disability (LTD) Claim: Matched Participants | Trial comparisons |
| Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants | Trial comparisons |
| Matched Treated: Short-term Disability vs Matched Untreated: Short-term Disability: Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07072793
GET https://conductscience.org/api/trials/v1/NCT07072793/registered?page=2